Clinical Trial Update: HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial update for GC1102 in HBV-associated liver transplant patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Liver Transplantation

Drugs mentioned

• GC1102 (Hepatitis B immunoglobulin, recombinant)

Snippet

Sponsor: Green Cross Corporation | Conditions: Hepatitis B Infection | Phase 2, Phase 3 | Status: UNKNOWN